CN103877029A - Preparation method of novel magnetic 5-fluorouracil carrying polylactic-co-glycolic acid (PLGA) material - Google Patents
Preparation method of novel magnetic 5-fluorouracil carrying polylactic-co-glycolic acid (PLGA) material Download PDFInfo
- Publication number
- CN103877029A CN103877029A CN201410084089.4A CN201410084089A CN103877029A CN 103877029 A CN103877029 A CN 103877029A CN 201410084089 A CN201410084089 A CN 201410084089A CN 103877029 A CN103877029 A CN 103877029A
- Authority
- CN
- China
- Prior art keywords
- plga
- preparation
- carrying
- solution
- fluorouracil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a preparation method of a novel magnetic 5-fluorouracil carrying polylactic-co-glycolic acid (PLGA) material. The preparation method of the novel magnetic 5-fluorouracil carrying PLGA material comprises the following steps: adding nano particles into a PLGA solution, dissolving 5-fluorouracil into dimethyl sulfoxide (DMSO), adding 5-Fu DMSO solution into the PLGA solution, and carrying out ultrasonic treatment, so that oil in oil (O/O) emulsion is obtained; then adding the O/O emulsion into PVA aqueous solution saturated by 5-Fu, stirring for evaporating a solvent, solidifying microspheres, washing with deionized water, and performing freeze drying, so that the magnetic 5-Fu carrying PLGA microspheres are obtained. The obtained drug carrying microspheres are uniform in particle size, and the particle size is 100-500 microns. Drug loading capacity of the microspheres is high and can be 10%. Drug releasing rate is regulated by regulating ratio of LA to GA in PLGA. As magnetic nano particles are introduced, under the control action of an external magnetic field, the drug carrying microspheres can be concentrated in a tumour region, and drug concentration in the tumour region is increased, so that apoptosis of tumour cells is quick, and harm of anti-tumour drug to normal cells is reduced to minimum. The preparation method of the novel magnetic 5-fluorouracil carrying PLGA material is simple and practicable, raw materials can be industrially produced, and the preparation method of the novel magnetic 5-fluorouracil carrying PLGA material has good popularization and application values.
Description
Technical field
The invention belongs to the preparation field of macromolecular material and medicament-carried nano material, the preparation method that is specifically related to a kind of novel magnetic and carries 5-fluorouracil PLGA (PLGA) material.
Background technology
PLGA (PLGA) is to be formed by two kinds of monomer-lactic acid and hydroxyacetic acid random copolymerization, is a kind of degradable functional polymer compound.There is good biocompatibility and biological degradability, nontoxic, it is degraded to carbon dioxide and water in vivo, and be difficult for accumulating in vivo, now be approved as pharmaceutic adjuvant by united states drug and food Surveillance Authority (FDA), be now widely used in pharmacy, medical engineering material and modernization industry field.Due to its excellent encystation and filming performance, existing multi-medicament adopts PLGA to prepare biodegradable microspheres realization to the gentle control of the slow release of medicine as framework material at present.
PLGA is the copolymer of lactic acid and hydroxyacetic acid, and lactic acid is more hydrophobic than hydroxyacetic acid, so the higher PLGA polymer of lactic acid content can be more hydrophobic, water absorption causes its degraded relatively slow at least.Therefore can realize the effective control to microsphere degraded and slow release by the kind and the copolymerization ratio that regulate two kinds of monomers (lactic acid and hydroxyacetic acid) in PLGA, research finds that the degradation rate of the PLGA that copolymerization ratio is 50:50 is the fastest in all proportionings.
5-fluorouracil (5-Fu) is a kind of clinical spectrum cancer therapy drug that is widely used in, and since nineteen fifty-seven, exploitation was come out, just in chemotherapy of tumors, has occupied important position.5-Fu is inhibited to the increment cycle of cell, its inhibitory action mechanism is mainly to suppress thymidylate synthase, blocking-up deoxidation pyrimidine nucleotide converts thymidine core to, disturb DNA synthetic, play antitumaous effect, thus and the propagation that can mix with pseudo-metabolite again inhibition tumor cell in RNA.5-Fu is widely used in clinical at present, and especially in treatment malignant tumor of digestive tract, there is no so far other drug can replace.But due to its poor selectivity to tumor cell, also larger to Normocellular toxicity, especially, in the situation that concentration is larger, it is more obvious to Normocellular toxic and side effects.And 5-Fu has again metabolism feature faster, and the half-life is in vivo short.Blood drug level that can not be continual and steady is for a long time to bring into play its antitumaous effect.While taking clinically, take intravenous injection or persistent instillation administration more more, but be often accompanied by bone marrow depression and a series of toxicity.In order to extend the drug effect of 5-Fu, reduce its toxic and side effects, adopt more and more in recent years carrier to prepare the method for medicine carrying microballoons.But 5-Fu is one is insoluble in water, be insoluble in the white crystals of ethanol, methanol and acetone and other organic solvent, aspect preparation year 5-Fu microsphere, running into a lot of difficult problems, maximum method of application makes pharmaceutical suspension in organic solution, prepare medicine carrying microballoons exactly at present, and result makes the drug loading of microsphere extremely low and unstable.In the time of room temperature, the dissolubility of 5-Fu in DMSO can reach more greatly 100mg/mL, and the present invention utilizes DMSO to dissolve 5-Fu, and the drug loading of the microsphere that the method for then mixing with the organic solution of PLGA finally makes can be up to 10%.In addition magnetic nano-particle is incorporated into the drug-supplying system that can make magnetic target in medicine carrying microballoons, under the guiding in magnetic field, MagneticphamaceuticaMicrophere Microphere in vivo displacement, location concentrates, and can effectively reduce the infringement of microsphere normal tissue in vitro.Meanwhile, microsphere can slowly discharge antitumor drug, extends drug effect and reduces whole body toxic and side effects simultaneously.
Utilize biocompatibility and the biological degradability of PLGA to prepare at medicine carrying microballoons, can be by regulating the two ratio of lactic acid and hydroxyacetic acid to control the rate of release of medicine carrying microballoons, dissolving 5-Fu by DMSO can make the drug loading of microsphere be increased to 10%, the function of its magnetic target is given in the introducing of magnetic nano-particle, when increasing the drug level of tumor locus and extend action time, also reduce it to Normocellular injury simultaneously, in chemotherapy of tumors, had good application prospect.
Summary of the invention
The object of the present invention is to provide a kind of novel magnetic to carry the preparation method of 5-fluorouracil PLGA (PLGA) microsphere.
The object of the invention is medicine 5-Fu to be dissolved in DMSO, and then mix with the dichloromethane solution of PLGA, increase the drug loading of final gained medicine carrying microballoons with this, in medicine carrying microballoons, introduce magnetic nanoparticle by the method that adds magnetic nano-particle in the dichloromethane solution of PLGA simultaneously, make the microsphere finally obtaining there is the characteristic of magnetic target administration.
The preparation that a kind of novel magnetic that the present invention proposes carries 5-fluorouracil PLGA (PLGA) microsphere, its concrete steps are as follows:
(1) PLGA (PLGA) is dissolved in to dichloromethane, in solution, adds magnetic nanoparticle, then ultrasonicly make it dispersed; In described PLGA, the copolymerization ratio of lactic acid (LA) and hydroxyacetic acid (GA) be in 75/25,50/50 or 80/20 any;
(2) 5-Fu is dissolved in DMSO, then is joined in the dichloromethane solution of the PLGA in step (1), the ultrasonic oily O/O emulsion of oil bag that obtains;
(3) oil of gained in step (2) is wrapped to oily O/O emulsion and dropwise join by the saturated PVA aqueous solution of 5-Fu, mechanical agitation 3～6h, makes dichloromethane volatilization, and microsphere solidifies;
(4) stop stirring, sedimentation, outwells supernatant liquid, collects lower floor's microsphere, uses deionized water wash three times;
(5) use buchner funnel sucking filtration, lyophilization, obtains MagneticphamaceuticaMicrophere Microphere.
In the present invention, the molecular weight of the PLGA in described step (1) is in 25000～30000 scopes;
In the present invention, in described step (1), magnetic nanoparticle comprises Fe
2o
3, MnFe
2o
4, CoFe
2o
4, particle diameter is within the scope of 5-20nm;
In the present invention, the concentration of the dichloromethane solution of PLGA is 80～120mg/mL;
In the present invention, ultrasonic power used is 250～300W;
In the present invention, the concentration of the DMSO solution of 5-Fu is 70～100mg/mL;
In the present invention, the concentration of PVA solution is 0.5～2%(mass fraction);
In the present invention, churned mechanically rotating speed is 280～420rpm;
In the present invention, lyophilization condition: temperature is-50～-55 ℃, and sublimation drying is 12～24h.
The invention has the advantages that: raw material sources are extensive, solvent, emulsifying agent etc. used all can obtain by suitability for industrialized production, and synthetic method is simple.The medicine carrying microballoons particle diameter of gained is more even, and particle diameter major control is within the scope of 100-500 μ m.The drug loading of microsphere is higher, can reach 10%.Can be by regulating the two ratio of lactic acid and hydroxyacetic acid in PLGA to realize slow release to MagneticphamaceuticaMicrophere Microphere and the Effective Regulation of degraded.The drug loading of PLGA microsphere gained that carries 5-Fu by this kind of prepared magnetic Nano of method is higher, and can realize the characteristic of target administration, when improving cancerous cell position local drug concentration, also cancer therapy drug is dropped to minimum to Normocellular injury.
Accompanying drawing explanation
Fig. 1: the structural representation of material of main part PLGA.
The specific embodiment
Be below to further illustrating of inventing, rather than limit range of application of the present invention.
This magnetic Nano carries the two ratio of lactic acid and hydroxyacetic acid in the material of main part of 5-Fu polylactic-co-glycolic acid microsphere can be confirmed by NMR.The particle diameter of gained magnetic Nano medicine carrying microballoons can be measured by dynamic laser light scattering apparatus (DLS).The surface topography of magnetic Nano medicine carrying microballoons can utilize scanning electron microscope (SEM) to characterize.The elution profiles of magnetic Nano medicine carrying microballoons can be measured by ultraviolet spectrophotometer.Embodiment 1
Take PLGA (PLGA) 200mg, wherein: lactic acid (LA) is 75:25 with the copolymerization ratio of hydroxyacetic acid (GA).Then be dissolved in dichloromethane, to the magnetic nanoparticle Fe that adds 5mg in solution
2o
3then ultrasonic 2min makes it dispersed; The 5-Fu of 200mg is dissolved in the DMSO of 2mL, then is joined in the dichloromethane solution of PLGA, ultrasonic 2min obtains the oily O/O emulsion of oil bag; The emulsion of gained is dropwise joined to 60mL by the saturated PVA aqueous solution of 5-Fu, and mechanical agitation 3h, makes dichloromethane volatilization, and microsphere solidifies; Stop stirring, sedimentation, outwells supernatant liquid, collects lower floor's microsphere, uses deionized water wash three times; Use buchner funnel sucking filtration, lyophilization obtains MagneticphamaceuticaMicrophere Microphere.
Embodiment 2
Take PLGA (PLGA) 200mg, wherein: lactic acid (LA) is 50:50 with the copolymerization ratio of hydroxyacetic acid (GA).Then be dissolved in dichloromethane, to the magnetic nanoparticle MnFe that adds 10mg in solution
2o
4then ultrasonic 2.5min makes it dispersed; The 5-Fu of 180mg is dissolved in the DMSO of 2mL, then is joined in the dichloromethane solution of PLGA, ultrasonic 2.5min obtains the oily O/O emulsion of oil bag; The emulsion of gained is dropwise joined to 70mL by the saturated PVA aqueous solution of 5-Fu, and mechanical agitation 4h, makes dichloromethane volatilization, and microsphere solidifies; Stop stirring, sedimentation, outwells supernatant liquid, collects lower floor's microsphere, uses deionized water wash three times; Use buchner funnel sucking filtration, lyophilization obtains MagneticphamaceuticaMicrophere Microphere.
Embodiment 3
Take PLGA (PLGA) 250mg, wherein: lactic acid (LA) is 80:20 with the copolymerization ratio of hydroxyacetic acid (GA).Then be dissolved in dichloromethane, to the magnetic nanoparticle CoFe that adds 5mg in solution
2o
4, then ultrasonic 1.5min makes it dispersed; The 5-Fu of 190mg is dissolved in the DMSO of 2mL, then is joined in the dichloromethane solution of PLGA, ultrasonic 3min obtains the oily O/O emulsion of oil bag; The emulsion of gained is dropwise joined to 70mL by the saturated PVA aqueous solution of 5-Fu, and mechanical agitation 3.5h, makes dichloromethane volatilization, and microsphere solidifies; Stop stirring, sedimentation, outwells supernatant liquid, collects lower floor's microsphere, uses deionized water wash three times; Use buchner funnel sucking filtration, lyophilization obtains MagneticphamaceuticaMicrophere Microphere.
Embodiment 4
Take PLGA (PLGA) 250mg, wherein: lactic acid (LA) is 75:25 with the copolymerization ratio of hydroxyacetic acid (GA).Then be dissolved in dichloromethane, to the magnetic nanoparticle Fe that adds 5mg in solution
2o
3, then ultrasonic 2min makes it dispersed; The 5-Fu of 250mg is dissolved in the DMSO of 2.5mL, then is joined in the dichloromethane solution of PLGA, ultrasonic 2.5min obtains the oily O/O emulsion of oil bag; The emulsion of gained is dropwise joined to 75mL by the saturated PVA aqueous solution of 5-Fu, and mechanical agitation 4h, makes dichloromethane volatilization, and microsphere solidifies; Stop stirring, sedimentation, outwells supernatant liquid, collects lower floor's microsphere, uses deionized water wash three times; Use buchner funnel sucking filtration, lyophilization obtains MagneticphamaceuticaMicrophere Microphere.
Embodiment 5
Take PLGA (PLGA) 250mg, wherein: lactic acid (LA) is 50:50 with the copolymerization ratio of hydroxyacetic acid (GA).Then be dissolved in dichloromethane, to the magnetic nanoparticle MnFe that adds 10mg in solution
2o
4, then ultrasonic 2.5min makes it dispersed; The 5-Fu of 250mg is dissolved in the DMSO of 2mL, then is joined in the dichloromethane solution of PLGA, ultrasonic 2.5min obtains the oily O/O emulsion of oil bag; The emulsion of gained is dropwise joined to 70mL by the saturated PVA aqueous solution of 5-Fu, and mechanical agitation 5h, makes dichloromethane volatilization, and microsphere solidifies; Stop stirring, sedimentation, outwells supernatant liquid, collects lower floor's microsphere, uses deionized water wash three times; Use buchner funnel sucking filtration, lyophilization obtains MagneticphamaceuticaMicrophere Microphere.
Embodiment 6
Take PLGA (PLGA) 300mg, wherein: lactic acid (LA) is 80:20 with the copolymerization ratio of hydroxyacetic acid (GA).Then be dissolved in dichloromethane, to the magnetic nanoparticle CoFe that adds 15mg in solution
2o
4, then ultrasonic 2min makes it dispersed; The 5-Fu of 250mg is dissolved in the DMSO of 2.5mL, then is joined in the dichloromethane solution of PLGA, ultrasonic 3min obtains the oily O/O emulsion of oil bag; The emulsion of gained is dropwise joined to 80mL by the saturated PVA aqueous solution of 5-Fu, and mechanical agitation 4h, makes dichloromethane volatilization, and microsphere solidifies; Stop stirring, sedimentation, outwells supernatant liquid, collects lower floor's microsphere, uses deionized water wash three times; Use buchner funnel sucking filtration, lyophilization obtains MagneticphamaceuticaMicrophere Microphere.
Claims (9)
1. novel magnetic carries a preparation method for 5-fluorouracil PLGA material, it is characterized in that concrete steps are as follows:
(1) PLGA is dissolved in to dichloromethane, in solution, adds magnetic nanoparticle, then ultrasonicly make it dispersed; In described PLGA, the copolymerization ratio of lactic acid and hydroxyacetic acid be in 75/25,50/50 or 80/20 any;
(2) 5-Fu is dissolved in DMSO, then is joined in the dichloromethane solution of the PLGA in step (1), the ultrasonic oily O/O emulsion of oil bag that obtains;
(3) oil of gained in step (2) is wrapped to oily O/O emulsion and dropwise join by the saturated PVA aqueous solution of 5-Fu, mechanical agitation 3～6h, makes dichloromethane volatilization, and microsphere solidifies;
(4) stop stirring, sedimentation, outwells supernatant liquid, collects lower floor's microsphere, uses deionized water wash three times;
(5) use buchner funnel sucking filtration, lyophilization, obtains MagneticphamaceuticaMicrophere Microphere.
2. preparation method according to claim 1, is characterized in that, in described step (1), the molecular weight of PLGA is 25000～30000.
3. preparation method according to claim 1, is characterized in that, in described step (1), magnetic nanoparticle comprises Fe
2o
3, MnFe
2o
4or CoFe
2o
4in any, particle diameter is 5-20nm.
4. preparation method according to claim 1, is characterized in that, in described step (1), the concentration of the dichloromethane solution of PLGA is 80～120mg/mL.
5. preparation method according to claim 1, is characterized in that, in described step (1), (2), ultrasonic power is 250～300W.
6. preparation method according to claim 1, is characterized in that, in described step (2), the concentration of the DMSO solution of 5-Fu is 70～100mg/mL.
7. preparation method according to claim 1, is characterized in that, in described step (3), the concentration of PVA solution is 0.5～2%(mass fraction).
8. preparation method according to claim 1, is characterized in that, in described step (3), churned mechanically rotating speed is 280～420rpm.
9. preparation method according to claim 1, is characterized in that, in described step (5), and lyophilization condition: temperature is-50～-55 ℃, and sublimation drying is 12～24h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410084089.4A CN103877029B (en) | 2014-03-10 | 2014-03-10 | A kind of magnetic carries the preparation method of 5-fluorouracil PLGA material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410084089.4A CN103877029B (en) | 2014-03-10 | 2014-03-10 | A kind of magnetic carries the preparation method of 5-fluorouracil PLGA material |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103877029A true CN103877029A (en) | 2014-06-25 |
| CN103877029B CN103877029B (en) | 2015-10-21 |
Family
ID=50946370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410084089.4A Expired - Fee Related CN103877029B (en) | 2014-03-10 | 2014-03-10 | A kind of magnetic carries the preparation method of 5-fluorouracil PLGA material |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103877029B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106420757A (en) * | 2016-09-23 | 2017-02-22 | 西南科技大学 | 5-fluorouracil/methoxy grafted kaolinite complex and preparation method thereof |
| CN107890465A (en) * | 2017-08-11 | 2018-04-10 | 深圳市第二人民医院 | A kind of preparation method for the magnetic Nano carried medicine sustained-release microsphere for wrapping up 5 fluorouracils |
| CN108114310A (en) * | 2017-12-22 | 2018-06-05 | 张海军 | A kind of degradable high drug load embolism microball and preparation method thereof |
| DE102018222807A1 (en) | 2017-12-22 | 2019-06-27 | Shandong Rientech Medical Technology Co., Ltd. | Degradable embolic microspheres with high drug loading capacity and process for their preparation |
| CN111803449A (en) * | 2020-06-15 | 2020-10-23 | 广东省医疗器械研究所 | Polymer microsphere for immune regulation and control and preparation method and application thereof |
| CN112791226A (en) * | 2019-11-14 | 2021-05-14 | 美国发现集团有限公司 | Nano robot with anti-tumor function and preparation method thereof |
| CN113082297A (en) * | 2021-04-15 | 2021-07-09 | 漯河医学高等专科学校 | Preparation method of superparamagnetic bone repair material |
| CN113440472A (en) * | 2021-06-25 | 2021-09-28 | 南方科技大学 | Polymer micro-robot and preparation method and application thereof |
| CN115300466A (en) * | 2022-08-08 | 2022-11-08 | 青岛市肿瘤医院 | Magnetic particle for enhancing tumor drug sensitivity and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101299998A (en) * | 2005-08-19 | 2008-11-05 | 麦格霍斯奈米生技股份有限公司 | Method for encapsulating therapeutic substances in cells |
| CN102342919A (en) * | 2011-10-14 | 2012-02-08 | 上海交通大学 | Preparation method for 5-fluorouracil/PLGA (Polylactic-co-Glycolic Acid) medicine carrying microspheres |
-
2014
- 2014-03-10 CN CN201410084089.4A patent/CN103877029B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101299998A (en) * | 2005-08-19 | 2008-11-05 | 麦格霍斯奈米生技股份有限公司 | Method for encapsulating therapeutic substances in cells |
| CN102716068A (en) * | 2005-08-19 | 2012-10-10 | 麦格霍斯奈米生技股份有限公司 | Method for carrying therapeutic substances into cells |
| CN102342919A (en) * | 2011-10-14 | 2012-02-08 | 上海交通大学 | Preparation method for 5-fluorouracil/PLGA (Polylactic-co-Glycolic Acid) medicine carrying microspheres |
Non-Patent Citations (2)
| Title |
|---|
| 孙美丽 等: "PLGA微球载药量和包封率的影响因素及控制", 《广东药学院学报》, vol. 27, no. 6, 31 December 2011 (2011-12-31) * |
| 赵仲 等: "装载于PLGA中的5-氟尿嘧啶缓释微球的制备及其体外释放的研究", 《现代生物医学进展》, vol. 11, no. 24, 31 December 2011 (2011-12-31) * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106420757A (en) * | 2016-09-23 | 2017-02-22 | 西南科技大学 | 5-fluorouracil/methoxy grafted kaolinite complex and preparation method thereof |
| CN107890465A (en) * | 2017-08-11 | 2018-04-10 | 深圳市第二人民医院 | A kind of preparation method for the magnetic Nano carried medicine sustained-release microsphere for wrapping up 5 fluorouracils |
| DE102018222807B4 (en) | 2017-12-22 | 2022-10-13 | Shandong Rientech Medical Technology Co., Ltd. | Degradable embolic microspheres with high drug loading capacity and method for their manufacture |
| CN108114310A (en) * | 2017-12-22 | 2018-06-05 | 张海军 | A kind of degradable high drug load embolism microball and preparation method thereof |
| DE102018222807A1 (en) | 2017-12-22 | 2019-06-27 | Shandong Rientech Medical Technology Co., Ltd. | Degradable embolic microspheres with high drug loading capacity and process for their preparation |
| US10624854B2 (en) | 2017-12-22 | 2020-04-21 | Shandong Rientech Medical Technology Co., Ltd | Method for preparing degradable drug-loaded microsphere for embolization, and product obtained therefrom |
| CN108114310B (en) * | 2017-12-22 | 2022-11-25 | 张海军 | Degradable drug-loaded microsphere and preparation method thereof |
| CN112791226A (en) * | 2019-11-14 | 2021-05-14 | 美国发现集团有限公司 | Nano robot with anti-tumor function and preparation method thereof |
| CN111803449A (en) * | 2020-06-15 | 2020-10-23 | 广东省医疗器械研究所 | Polymer microsphere for immune regulation and control and preparation method and application thereof |
| CN111803449B (en) * | 2020-06-15 | 2023-06-30 | 广东省医疗器械研究所 | Polymer microsphere for immune regulation and control as well as preparation method and application thereof |
| CN113082297B (en) * | 2021-04-15 | 2022-02-25 | 漯河医学高等专科学校 | Preparation method of superparamagnetic bone repair material |
| CN113082297A (en) * | 2021-04-15 | 2021-07-09 | 漯河医学高等专科学校 | Preparation method of superparamagnetic bone repair material |
| CN113440472A (en) * | 2021-06-25 | 2021-09-28 | 南方科技大学 | Polymer micro-robot and preparation method and application thereof |
| CN115300466A (en) * | 2022-08-08 | 2022-11-08 | 青岛市肿瘤医院 | Magnetic particle for enhancing tumor drug sensitivity and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103877029B (en) | 2015-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103877029B (en) | A kind of magnetic carries the preparation method of 5-fluorouracil PLGA material | |
| Song et al. | An oral drug delivery system with programmed drug release and imaging properties for orthotopic colon cancer therapy | |
| US10624854B2 (en) | Method for preparing degradable drug-loaded microsphere for embolization, and product obtained therefrom | |
| Liu et al. | An injectable nanocomposite hydrogel co-constructed with gold nanorods and paclitaxel-loaded nanoparticles for local chemo-photothermal synergetic cancer therapy | |
| He et al. | Localized multidrug co-delivery by injectable self-crosslinking hydrogel for synergistic combinational chemotherapy | |
| Cao et al. | Polymer-controlled core–shell nanoparticles: a novel strategy for sequential drug release | |
| CN104288111A (en) | Ginsenoside Rg3 poly(lactic-co-glycolic acid) nano microsphere and preparation method thereof | |
| CN100344277C (en) | Nano-magnetic medicinal microglobule, its preparation method and application | |
| Wu et al. | A Bi 2 S 3-embedded gellan gum hydrogel for localized tumor photothermal/antiangiogenic therapy | |
| CN102908318B (en) | 10-hydroxycamptothecine nanometer microsphere and preparation method thereof | |
| Moghaddam et al. | Fabrication of carboxymethyl chitosan nanoparticles to deliver paclitaxel for melanoma treatment | |
| Wang et al. | Polyoxometalate–covalent organic framework hybrid materials for pH-responsive photothermal tumor therapy | |
| CN103169662A (en) | Paclitaxel polymer nanoparticle and preparation method | |
| CN105997943A (en) | Nano-particles of human serum albumin loaded camptothecin drugs, as well as preparation method and application thereof | |
| CN106606778B (en) | Choline phosphate-containing polymer coated core-shell type magnetic composite particle and preparation method thereof | |
| CN103768598B (en) | A kind of implantable fullerene polylactic acid is from the preparation method of reunion carried medicine sustained-release microsphere and application | |
| CN106361724B (en) | A sustained release nanometer microsphere composition of 20(R) -ginsenoside Rg3 and its preparation method | |
| Wang et al. | Tunable Zeolitic Imidazolate Framework‐8 Nanoparticles for Biomedical Applications | |
| CN103877625B (en) | PLGA (poly(lactic-co-glycolic acid))/bletilla composite microsphere for embolism and preparation method thereof | |
| Xing et al. | Engineering near-infrared laser-activated gold nanorod vesicles with upper critical solution temperature for photothermal therapy and chemotherapy | |
| Zhang et al. | Sustained drug release and cancer treatment by an injectable and biodegradable cyanoacrylate-based local drug delivery system | |
| Yang et al. | Poly (D, L-lactide-co-glycolide) nanoparticles encapsulated fluorescent isothiocyanate and paclitaxol: preparation, release kinetics and anticancer effect | |
| CN105434399B (en) | A kind of renal cell carcinoma treatment medicine Sutent PLGA/Fe3O4 complex microspheres and preparation method thereof | |
| Xu et al. | Metal-polyphenol polymer modified polydopamine for chemo-photothermal therapy | |
| WO2018064963A1 (en) | Use of fullerene structure in preparation of medicament for treating tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151021 Termination date: 20180310 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |